Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2010
BIOSANTE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-31812
|
|
58-2301143 |
| |
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
| |
|
|
111 Barclay Boulevard
Lincolnshire, Illinois
|
|
60069 |
| |
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (847) 478-0500
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8
— Other Events
Item 8.01.
Other Events.
BioSante Pharmaceuticals, Inc. is filing this current report on Form 8-K to file as an exhibit
the license agreement dated December 3, 2008 between BioSante Pharmaceuticals, Inc. and Azur Pharma
International II, Limited, as amended.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit |
|
|
| No. |
|
Description |
10.1
|
|
License Agreement dated December 3, 2008 between BioSante
Pharmaceuticals, Inc. and Azur Pharma International II,
Limited* |
|
|
|
10.2
|
|
Amendment No. 1 to License Agreement and Asset Purchase
Agreement dated December 7, 2009 between BioSante
Pharmaceuticals, Inc. and Azur Pharma International II,
Limited* |
* Confidential treatment has been requested with respect to
designated portions of this document. Such portions have been omitted
and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
BIOSANTE PHARMACEUTICALS, INC.
|
|
| |
By: |
/s/ Phillip B. Donenberg
|
|
| |
|
Phillip B. Donenberg |
|
| |
|
Chief Financial Officer, Treasurer and Secretary |
|
| |
Dated: May 3, 2010
BIOSANTE PHARMACEUTICALS, INC.
FORM 8-K
Exhibit Index
| |
|
|
|
|
| Exhibit No. |
|
Description |
|
Method of Filing |
10.1
|
|
License Agreement dated December 3, 2008
between BioSante Pharmaceuticals, Inc.
and Azur Pharma International II,
Limited (*)
|
|
Filed herewith |
|
|
|
|
|
10.2
|
|
Amendment No. 1 to License Agreement and
Asset Purchase Agreement dated December
7, 2009 between BioSante
Pharmaceuticals, Inc. and Azur Pharma
International II, Limited (*)
|
|
Filed herewith |
* Confidential treatment has been requested with respect to
designated portions of this document. Such portions have been omitted
and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.